HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Parlux

This article was originally published in The Rose Sheet

Executive Summary

Final second quarter results, originally expected the first week of November, will not be released until Nov. 11 due to a power outage in Parlux' Florida-based office and distribution facility caused by Hurricane Wilma, fragrance marketer announces Nov. 1. The company has resumed normal operations and expects to meet previous guidance and holiday commitments. Second quarter sales are expected to be up 74% to approximately $39 mil.-$40 mil., company reported Oct. 6 (1"The Rose Sheet" Oct. 10, 2005, In Brief). Firm anticipates restarting stock buyback program as the hurricane "unreasonably depressed" stock market price. Parlux markets scents including Guess? and Just Me by Paris Hilton...

You may also be interested in...



Parlux

Second quarter sales are expected to be up 74% to approximately $39 mil.-$40 mil., bolstered by international rollout of Guess? and Maria Sharapova fragrances as well as new Paris Hilton scent, Just Me, firm announces Oct. 6. Company's Perry Ellis fragrance portfolio will be strengthened by the launch of Perry 18 next summer, Parlux adds. Firm also reiterates previously reported fiscal year sales guidance of $190 mil.-$210 mil. Parlux will release final Q2 results the first week in November...

Rising Costs, Price Pressure Usher In Uncertain Year Of The Rat In China

Once the world's factory, China has seen costs inch up while drug prices are being cut deeply by centralized procurement schemes. As uncertainties mount, companies need to focus on improving process and scale-up technology, suggested industry observers at a JPM panel discussion on innovation and market access challenges.

Biocon-Mylan's Plans For Broader US Fulphila Access, Glargine On Track

Biocon-Mylan press ahead with plans to broaden patient access in the US to biosimilar pegfilgrastim and are enthused with the initial uptake for their trastuzumab biosimilar ahead of more upcoming competition. A mid-2020 US launch for partnered insulin glargine is also on course.

UsernamePublicRestriction

Register

RS013485

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel